繁中

CONTACT US

*Category

Required

*Name

Required

*Title

Required

Company

Company Type

*Country/Area

Required

*Tel

Required

*Email

Required

Job Title

*Message

Required

*Verification code

Required

AmCad BioMed Corporation

+886-2-2713-6227

marketing@amcadbiomed.com

Fl.5-2, No. 167, Fu Hsing N. RD. Taipei 105, Taiwan

ABOUT US

MILESTONES

Event

R&D

Management

2021

September

-Advanced AmCAD-UT with AI contouring function obtains FDA 510(k) approval

2020

November

-AmCAD-CA obtained Taiwan Excellence Award 2021

2019

November

-AmCAD-UO received the Gold Award of Drug Research and Development Science and Technology Award

-Received TFDA approval for AmCAD-UO

July

-AmCAD-UO awarded the annual Taiwan Bio-Industry Organization awards in Innovation of the Year category

January

-Received U.S. FDA 510(k) clearance for AmCAD-UO

2018

November

-AmCAD-UO obtained Taiwan Excellence Award 2019

October

-Received CE Marking approval for AmCAD-UO

2017

December

-AmCAD-UT awarded Taiwan Excellence Award 2018

July

-Received CFDA approval for AmCAD-UT Detection

May

-Received U.S. FDA 510(k) clearance for AmCAD-US

April

-Received U.S. FDA 510(k) clearance for AmCAD-UV

2016

December

-AmCAD-CA awarded the 13th National Innovation Award

-AmCAD-UT® Detection received the Gold Award of Drug Research and Development Science and Technology Award

July

-Received Frost & Sullivan Taiwan Business Best Practice Award

-Received Go-Global Silver Medal Award of Taipei Biotechnology Award

June

-Received TFDA clearance for upgrade version of AmCAD-UT® Detection

March

-Received CE Marking approval for AmCAD-UV

April

-Granted distribution right of China to Huajin Yike Pharmaceutical, based in Zhejiang Province, for AmCAD-UT® Detection with a US$5 million payment obligation

-Received CE Marking approval for AmCAD-US

2015

December

-Received Silver Award of National Biotechnology and Medical Care Quality Award for AmCAD-UT® Detection

March

-Listed on Taiwan’s OTC Stock Market (Code: 4188)

January

-Received TFDA clearance for AmCAD-UT® Detection
 

2014

April

-Received CE Marking approval for AmCAD-UT Detection 2.0
 

2013

December

-Listed on Taiwan’s Emerging Stock Market (Code: 4188)

November

-Recommended by Industrial Development Bureau (IDB), MoEA as a qualified technology enterprise for IPO application

October

-Received U.S. FDA 510(k) clearance for AmCAD-UT Detection 2.0

September

-Received Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Award

February

-Started to receive patent approvals for its core technologies in U.S., Singapore, Taiwan, etc

2012

March

-Awarded R&D project Grant, “Development of Calibration Method for Compatibility with Various US Machines”, by Taipei City Government

2011

November

-Received GMP certification for Software Manufacturing

May

-Received the “Certificate of Manufacturer of Medical Devices” after its factory establishment

2010

May

-Received The 7th National Innovation Award

2009

December

-Identified as a company of the emerging medical health care industry in Taiwan by Industrial Development Bureau (IDB)

July

-Awarded Industrial Technology Development Program (TDP) Grant “Computer-assisted thyroid disease ultrasound diagnostic system” by MoEA

June

-Received “Important Emerging Strategic Industry” status approval letter by Industrial Development Bureau(IDB) of Ministry of Economic Affairs(MoEA)

January

-Transferred technology with exclusive authorization from National Taiwan University.

2008

December

-AmCad BioMed Corporation(AmCad) was founded.

Copyright © 2019 AmCad BioMed Corporation. All Rights Reserved. Web Design- rIDEA